Evidence map›Paper›PMID 39117768›Full record

ReviewMedical oncology (Northwood, London, England)2024

Emerging roles of the chromatin remodeler MORC2 in cancer metabolism.

Bibhukalyan Mohapatra, Suresh B Pakala

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bibhukalyan MohapatraDepartment of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500 046, India.
Suresh B PakalaDepartment of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500 046, India. pakalasb@uohyd.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is characterized by metabolic reprogramming in cancer cells, which is crucial for tumorigenesis. The highly deregulated chromatin remodeler MORC2 contributes to cell proliferation, invasion, migration, DNA repair, and chemoresistance. MORC2 also plays a key role in metabolic reprogramming, including lipogenesis, glucose, and glutamine metabolism. A recent study showed that MORC2-regulated glucose metabolism affects the expression of E-cadherin, a crucial protein in the epithelial-to-mesenchymal transition. This review discusses recent developments in MORC2 regulated cancer cell metabolism and its role in cancer progression.

Indexed as

Chromatin Assembly and DisassemblyNeoplasmsTranscription FactorsAnimalsEpithelial-Mesenchymal TransitionHumansSMARCA2 protein, humanTranscription FactorsGlucose metabolismGlutamine metabolismLipogenesisMORC2

Identifiers

PMID39117768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.